#AAN2018 – IONIS-HTTRx Shows Promise in Phase 1/2 Trial to Treat Early-stage Huntington’s

The investigative therapy IONIS-HTTRx effectively reduced levels of the protein responsible for Huntington’s disease in early-stage patients, according to the findings of an ongoing Phase 1/2 clinical trial. The results also revealed that IONIS-HTTRx is generally safe and well-tolerated by patients, further demonstrating its potential as an alternative therapeutic option…

Strict Diet Control in Mouse Study Seen as Potential Huntington’s Disease Therapeutic Approach

Following a strict diet schedule helped clear away the protein responsible for Huntington’s disease in mice, according to researchers in Canada. The study, “Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease,” was published in the journal Acta Neuropathologica Communications. The buildup of mutant huntingtin…